US2022204924A1PendingUtilityA1

Engineered endothelial cells expressing an ets transcription factor

57
Assignee: ANGIOCRINE BIOSCIENCE INCPriority: Jul 20, 2015Filed: Mar 7, 2021Published: Jun 30, 2022
Est. expiryJul 20, 2035(~9 yrs left)· nominal 20-yr term from priority
Inventors:Daniel Joseph NolanPaul William FinneganMichael GinsbergClaude Geoffrey Davis
C12N 5/069C12N 2710/10322C12N 15/86C12N 2501/60A61K 38/162A61K 38/1709C12N 7/00A61P 17/02C12N 2740/15043A61K 35/28C07K 14/005C12N 2510/00A61K 35/44C12N 5/0647C12N 2502/1171C07K 14/47A61P 9/14C12N 2500/90C12N 2501/998
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

In some aspects the present invention relates to engineered endothelial cells, such as E4ORF1+ ETV2+ engineered endothelial cells. In other aspects the present invention relates to methods of making such engineered endothelial cells, and methods of using such engineered endothelial cells, for example in co-culture applications.

Claims

exact text as granted — not AI-modified
1 - 56 . (canceled) 
     
     
         57 . A composition comprising E4ORF1+ ETV2+ umbilical vein endothelial cells (UVECs), wherein the UVECs comprise a recombinant nucleic acid sequence that encodes an ETV2 polypeptide and a recombinant nucleic acid sequence that encodes an adenovirus E4ORF1 polypeptide. 
     
     
         58 . The composition of  claim 57 , wherein the UVECs do not comprise an entire adenovirus E4 region. 
     
     
         59 . The composition of  claim 57 , wherein the UVECs do not comprise nucleic acid sequences that encode E4ORF2, E4ORF3, E4ORF4, or E4ORF5 polypeptides. 
     
     
         60 . The composition of  claim 57 , wherein at least about 50% of the cells in the composition are E4ORF1+ ETV2+ UVECs. 
     
     
         61 . The composition of  claim 57 , wherein at least about 75% of the cells in the composition are E4ORF1+ ETV2+ UVECs. 
     
     
         62 . The composition of  claim 57 , wherein at least about 85% of the cells in the composition are E4ORF1+ ETV2+ UVECs. 
     
     
         63 . The composition of  claim 57 , wherein at least about 95% of the cells in the composition are E4ORF1+ ETV2+ UVECs. 
     
     
         64 . The composition of  claim 57 , wherein the UVECs are human umbilical vein endothelial cells (HUVECs). 
     
     
         65 . The composition of  claim 58 , wherein the UVECs are HUVECs. 
     
     
         66 . The composition of  claim 59 , wherein the UVECs are HUVECs. 
     
     
         67 . The composition of  claim 60 , wherein the UVECs are HUVECs. 
     
     
         68 . The composition of  claim 61 , wherein the UVECs are HUVECs. 
     
     
         69 . The composition of  claim 62 , wherein the UVECs are HUVECs. 
     
     
         70 . The composition of  claim 63 , wherein the UVECs are HUVECs.

Join the waitlist — get patent alerts

Track US2022204924A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.